2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-155452
    SG62 250683-07-9
    SG62 is an amine nicotine haptenand can be used for the study of nicotine dependence.
    SG62
  • HY-155455
    Dicamba-(CH2)5-acid 2892008-07-8
    Hapten Dca is an immunizing hapten. Hapten Dca is activated by a solution of N, N′-disuccinimidyl carbonate. Hapten Dca with a carboxyl functional group is conjugated to proteins.
    Dicamba-(CH2)5-acid
  • HY-155458
    HYDAMTIQ 1201832-32-7
    HYDAMTIQ is a PARP-1/2 inhibitor (IC50: 29-38 nM) with anticancer, anti-inflammatory, and ischemic protective effects. HYDAMTIQ inhibits pulmonary PARP activity, is effective against allergen-induced cough and dyspnea, and inhibits bronchial hyperresponsiveness to methacholine. HYDAMTIQ has broad-spectrum tumor suppressor effects, including ovarian and breast cancers, prostate and pancreatic tumors, and glioblastoma multiforme. HYDAMTIQ has demonstrated in vivo efficacy in animal models of cerebral ischemia, asthma, cancer, and more.
    HYDAMTIQ
  • HY-155487
    JTE-151 1404380-58-0
    JTE-151 is a RORγ inhibitor, which can suppress overactive immune response through inhibition of RORγ related to the activation of Th17 cells, making JTE-151 possible to be used in autoimmune disease research.
    JTE-151
  • HY-155494
    trans-Stilbene-NHCO-(CH2)3-acid 316173-40-7
    trans-Stilbene-NHCO-(CH2)3-acid, a trans-stilbene hapten, can be used to elicit a panel of monoclonal antibodies that display a range of fluorescent spectral behavior.
    trans-Stilbene-NHCO-(CH2)3-acid
  • HY-155505
    AHR agonist 4 2953023-30-6
    AHR agonist 4 (compound 24e) is an agonist of Aryl hydrocarbon receptor (AHR), assocaited with the immune balance of Th17/22 and Treg cells. AHR agonist 4 serves as a lead compound for anti-psoriasis drug, alleviates imiquimod (IMQ)-induced psoriasis-like skin lesion. AHR agonist 4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    AHR agonist 4
  • HY-15550R
    4'-Hydroxy diclofenac (Standard) 64118-84-9
    4'-Hydroxy diclofenac (Standard) is the analytical standard of 4'-Hydroxy diclofenac. This product is intended for research and analytical applications. 4'-Hydroxy diclofenac is an orally active metabolite of Diclofenac (HY-15036) by cytochrome P450 2C9 (CYP2C9). 4'-Hydroxy diclofenac has anti-inflammatory and analgesic properties.
    4'-Hydroxy diclofenac (Standard)
  • HY-155514
    HA-IN-1
    HA-IN-1 (compound 5g) is a Hemagglutinin (HA) ligand with high affinity, targeting to the trypsin cleavage site of HA. HA-IN-1 inhibits HA-mediated membrane fusion and reduces the pulmonary virus titer in vivo. HA-IN-1 is a potential influenza A virus (IAV) inhibitor, and an anti-influenza agent.
    HA-IN-1
  • HY-155517
    INF200
    INF200 (compound 5) is a sulfonylurea-based inhibitor of NLRP3 and NLRP3-mediated pyroptosis. INF200 has beneficial cardiometabolic effects in rat model of high-fat diet (HFD)-induced metaflammation，and shows anti-inflammatory activity to (10 μM) decreases IL-1β release in human macrophages. INF200 improves glucose and lipid profiles，and attenuates systemic inflammation and biomarkers of cardiac dysfunction (particularly BNP). INF200 also improves myocardial damage-dependent ischemia/reperfusion injury (IRI) in hemodynamic evaluation.
    INF200
  • HY-155518
    IRAK4-IN-25 2952533-47-8
    IRAK4-IN-25 (compound 38) is an orally acitve and potent IRAK4 inhibitor (IC50=7.3 nM), with low clearance (Cl=12 mL/min/kg). IRAK4-IN-25 inhibits production of pro-inflammatory cytokines, and shows in vitro safety and ADME profiles. IRAK4-IN-25 can be used for research in inflammatory and autoimmune disorders.
    IRAK4-IN-25
  • HY-155519
    IRAK4-IN-26 2952533-49-0
    IRAK4-IN-26 (Compound 21) is a IRAK4 inhibitor (IC50: 6.2 nM). IRAK4-IN-26 displays an oral bioavailability of 21%. IRAK4-IN-26 can be used for research of inflammatory and autoimmune disorders.
    IRAK4-IN-26
  • HY-155548
    RORγt inverse agonist 31
    RORγt inverse agonist 31 (14g) is a potent retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonist, with an IC50 of 0.428 μM. RORγt inverse agonist 31 can alleviate the severity of Imiquimod (HY-B0180)-induced psoriasis in mice.
    RORγt inverse agonist 31
  • HY-155550
    CSF1R-IN-17
    CSF1R-IN-17 (compound 9) is a potent and selective CSF1R antagonist, with an IC50 of 0.2 nM. CSF1R-IN-17 can inhibit osteoclast differentiation.
    CSF1R-IN-17
  • HY-155551
    Anti-inflammatory agent 46 2925586-96-3
    Anti-inflammatory agent 46 (compound 7h) is an anti-inflammatory agent with nitric oxide (NO) inhibitory effect. Anti-inflammatory agent 46 binds to iNOS with low energies, inhibits swelling in mice (at dose of 10 mg/kg).
    Anti-inflammatory agent 46
  • HY-155568
    Anti-inflammatory agent 47 2925288-12-4
    Flo8 is a potent anti-inflammatory and antioxidant compound. Flo8 inhibits the release of intracellular reactive oxygen species (ROS) and nitric oxide (NO) and suppresses neuronal apoptotic by inhibiting inflammatory and apoptotic signaling pathways. Flo8 can be used for Parkinson's Disease (PD) research.
    Anti-inflammatory agent 47
  • HY-15556A
    GSK269962A hydrochloride 2095432-71-4 99.73%
    GSK269962A hydrochloride (GSK 269962 hydrochloride) is a potent ROCK inhibitor with IC50s of 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively. GSK269962A hydrochloride has anti-inflammatory and vasodilatory activities.
    GSK269962A hydrochloride
  • HY-155572
    Nrf2 activator-8
    Nrf2 activator-8 (compound 10e) is a Nrf2 activator (EC50=37.9 nM). Nrf2 activator-8 exhibits remarkable antioxidant and anti-inflammatory effects in BV-2 microglial cells. Nrf2 activator-8 can significantly restore spatial memory deficits in a mouse model of lipopolysaccharide (LPS)-induced neuroinflammation.
    Nrf2 activator-8
  • HY-155593
    JNK-1-IN-2
    JNK-1-IN-2 (Compound c6) is a JNK-1 inhibitor (IC50: 33.5 nM). JNK-1-IN-2 also inhibits JNK-2 and JNK-3 with IC50s of 112.9 nM and 33.2 nM. JNK-1-IN-2 inhibits the phosphorylation of c-Jun. JNK-1-IN-2 reverses lung impairment. JNK-1-IN-2 can be used for research of pulmonary fibrosis.
    JNK-1-IN-2
  • HY-155597
    h-NTPDase8-IN-1 716358-51-9
    h-NTPDase8-IN-1 (compound 2d) is a sulfamoyl-benzamides based and selective inhibitor for h-NTPDases8 (IC50=0.28 μM). h-NTPDases8 is involved in a variety of physiological and pathological functions，such as thrombosis，diabetes，inflammation，and cancer.
    h-NTPDase8-IN-1
  • HY-155611
    Cathepsin C-IN-6
    Cathepsin C-IN-6 (compound 2) is a E-64c-hydrazideas based inhibitor of cathepsin C with anti-inflammatory activity. Cathepsin C-IN-6 inhibts activation of neutrophil elastase，exhibits potential efficacy in inflammatory diseases with high neutrophil load (e.g.，chronic obstructive pulmonary disease).
    Cathepsin C-IN-6
Cat. No. Product Name / Synonyms Application Reactivity